---
title: "Ascentage Pharma Group International ADR - W/I (AAPGV.US)"
type: "Symbol"
locale: "en"
url: "https://longbridge.com/en/quote/AAPGV.US.md"
symbol: "AAPGV.US"
name: "Ascentage Pharma Group International ADR - W/I"
industry: "Biotechnology"
datetime: "2026-03-03T10:48:54.769Z"
locales:
  - [en](https://longbridge.com/en/quote/AAPGV.US.md)
  - [zh-CN](https://longbridge.com/zh-CN/quote/AAPGV.US.md)
  - [zh-HK](https://longbridge.com/zh-HK/quote/AAPGV.US.md)
---

> Supported Languages: [简体中文](https://longbridge.com/zh-CN/quote/AAPGV.US.md) | [繁體中文](https://longbridge.com/zh-HK/quote/AAPGV.US.md)


# Ascentage Pharma Group International ADR - W/I (AAPGV.US)

| Item | Detail |
|------|--------|
| Industry | Biotechnology |
| Exchange | US Market |

## Key Drivers
> *AI-analyzed key factors driving this stock's performance*


## Longbridge Financial Score™: C
> *Longbridge Financial Score™ — Proprietary multi-factor rating model by Longbridge*
> Updated: 2026-03-03T04:30:15.000Z

**Overall: C (0.53)**

**Industry**: Biotechnology

| Metric | Value |
|--------|-------|
| Industry Ranking | 187 / 405 |
| Industry Median | D |
| Industry Average | C |

- **Style**: Blend - Stocks in which the company has both growth and mature businesses.
- **Scale**: Small - The company's operation has a high degree of growth and volatility, making it easy to achieve high investment returns.

**Multi Score**: C

#### Style Score Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Revenue YoY | 244.05% |  |
| Net Profit YoY | 59.90% |  |
| P/B Ratio | 0.00 |  |
| Dividend Ratio | 0.00% |  |

#### Size Score Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Market Cap | 0.00 |  |
| Revenue | 125056513.60 |  |

#### Multi Score Score: C

| Indicator | Value | Rating |
|-----------|-------|--------|
| ROE | -53.13% | E |
| Profit Margin | -39.90% | E |
| Gross Margin | 98.17% | A |
| Revenue YoY | 244.05% | A |
| Net Profit YoY | 59.90% | B |
| Total Assets YoY | 6.50% | B |
| Net Assets YoY | 29.39% | A |
| Cash Flow Margin | -250.64% | D |
| OCF YoY | 244.05% | A |
| Turnover | 0.30 | D |
| Gearing Ratio | 75.01% | E |

```chart-data:radar
{
  "title": "Longbridge Financial Score - Ascentage Pharma Group International ADR - W/I",
  "chart_type": "radar",
  "dimensions": [
    {
      "name": "Style Score",
      "grade": "",
      "indicators": [
        {
          "name": "Revenue YoY",
          "value": "244.05%",
          "rating": ""
        },
        {
          "name": "Net Profit YoY",
          "value": "59.90%",
          "rating": ""
        },
        {
          "name": "P/B Ratio",
          "value": "0.00",
          "rating": ""
        },
        {
          "name": "Dividend Ratio",
          "value": "0.00%",
          "rating": ""
        }
      ]
    },
    {
      "name": "Size Score",
      "grade": "",
      "indicators": [
        {
          "name": "Market Cap",
          "value": "0.00",
          "rating": ""
        },
        {
          "name": "Revenue",
          "value": "125056513.60",
          "rating": ""
        }
      ]
    },
    {
      "name": "Multi Score",
      "grade": "C",
      "indicators": [
        {
          "name": "ROE",
          "value": "-53.13%",
          "rating": "E"
        },
        {
          "name": "Profit Margin",
          "value": "-39.90%",
          "rating": "E"
        },
        {
          "name": "Gross Margin",
          "value": "98.17%",
          "rating": "A"
        },
        {
          "name": "Revenue YoY",
          "value": "244.05%",
          "rating": "A"
        },
        {
          "name": "Net Profit YoY",
          "value": "59.90%",
          "rating": "B"
        },
        {
          "name": "Total Assets YoY",
          "value": "6.50%",
          "rating": "B"
        },
        {
          "name": "Net Assets YoY",
          "value": "29.39%",
          "rating": "A"
        },
        {
          "name": "Cash Flow Margin",
          "value": "-250.64%",
          "rating": "D"
        },
        {
          "name": "OCF YoY",
          "value": "244.05%",
          "rating": "A"
        },
        {
          "name": "Turnover",
          "value": "0.30",
          "rating": "D"
        },
        {
          "name": "Gearing Ratio",
          "value": "75.01%",
          "rating": "E"
        }
      ]
    }
  ]
}
```

## Valuation Analysis

| Metric | Current | Industry Ranking | High | Median | Low |
|--------|---------|-----------------|------|--------|-----|
| Dividend Yield | 0.00% | - | - | - | - |

## Peer Comparison

| Rank | Name | Profit | Growth | Operation | Security | Cash | Rating |
| --- | --- | --- | --- | --- | --- | --- | --- |
| 01 | Kiniksa Pharmaceuticals (KNSA.US) | B | A | A | B | A | A |
| 02 | Stoke Therapeutics (STOK.US) | A | A | B | A | B | A |
| 03 | MiMedx (MDXG.US) | A | B | A | B | B | A |
| 04 | Rigel Pharma (RIGL.US) | A | A | A | C | B | A |
| 05 | OpGen (OPGN.US) | B | A | A | A | B | A |

## References

- [Company Overview — Profile, executives, shareholders, business breakdown](https://longbridge.com/en/quote/AAPGV.US/overview.md)
- [Financial Reports — Income, balance sheet, cash flow, dividends](https://longbridge.com/en/quote/AAPGV.US/norm.md)
- [Related News](https://longbridge.com/en/quote/AAPGV.US/news.md)
- [Filings — Company announcements and regulatory filings](https://longbridge.com/en/quote/AAPGV.US/filings.md)

---

> **Disclaimer: This article is for reference only and does not constitute any investment advice.**